GALECTIN THERAPEUTICS INC. — Net Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/ce7abd6c-5c9f-4baa-a94d-9c8f7b148283/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-30.8M | 2025-01-01 – 2025-12-31 | evidence 0001140361-26-012155 |
| FY 2024 | $-47.0M | 2024-01-01 – 2024-12-31 | evidence 0001140361-25-011169 |
| FY 2023 | $-41.1M | 2023-01-01 – 2023-12-31 | evidence 0001140361-24-016452 |
| FY 2022 | $-38.8M | 2022-01-01 – 2022-12-31 | evidence 0001140361-23-014658 |
| FY 2021 | $-30.5M | 2021-01-01 – 2021-12-31 | evidence 0001140361-22-012058 |
| FY 2020 | $-23.5M | 2020-01-01 – 2020-12-31 | evidence 0001193125-21-101402 |
| FY 2019 | $-13.3M | 2019-01-01 – 2019-12-31 | evidence 0001193125-20-073907 |
| FY 2018 | $-13.9M | 2018-01-01 – 2018-12-31 | evidence 0001193125-19-064705 |
| FY 2017 | $-16.2M | 2017-01-01 – 2017-12-31 | evidence 0001193125-18-100592 |
| FY 2016 | $-21.4M | 2016-01-01 – 2016-12-31 | evidence 0001193125-17-098753 |
| FY 2015 | $-20.0M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-504330 |
| FY 2014 | $-15.8M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-096928 |
| FY 2013 | $-89.2M | 2000-07-11 – 2014-03-31 | evidence 0001193125-14-197112 |
| FY 2012 | $-75.2M | 2000-07-11 – 2013-03-31 | evidence 0001193125-13-213107 |
| FY 2011 | $-64.3M | 2000-07-10 – 2012-03-31 | evidence 0001193125-12-227792 |
| FY 2010 | $-5.6M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-143150 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).